First Integrated Pharmacogenomics and Metabolomics Platform Offers Potential to Improve Patient Outcomes, Lower Costs in Medication Therapy
Ann Arbor, MI – November 14, 2019 – Phenomics Health Inc., a bioinformatics platform-based precision medicine company, today announced it has acquired the patented pharmacometabolomic technology portfolio of Precera Bioscience, based in Franklin, Tenn.
Phenomics Health plans to integrate the new technology with its own patented, advanced pharmacogenomics platform to offer healthcare providers a more complete view of patients’ potential and actual response to medications than is currently available.
To be marketed under the PrecīsMed brand and licensed to clinical laboratories and healthcare systems, this patented pharmacometabolomic technology enables detection, quantitative measurement, and comprehensive assessment of more than 200 medications in a patient’s bloodstream.
Combined with Phenomics Health’s technology, the resulting information from PrecīsMed will help clinicians personalize drug therapy by determining what medications and dose a patient is actually taking (whether prescribed or not), drug-drug interactions, and how genetics may impact the body’s ability to process those medications.
“This is the first time that both advanced pharmacogenomics and pharmacometabolomics platforms have come together under one roof,” said Dr. James S. Burns, co-founder, Chairman and President, Phenomics Health. “PrecīsMed could help improve patient treatment outcomes, avoid adverse drug reactions, and reduce patient treatment costs – the real definition of precision medicine.”